Hundreds of adults and teenagers in England with a rare, inherited eye disease will benefit from a new treatment after NICE today recommended idebenone for visual impairment caused by Leber's ...

NICE and the Medicines and Healthcare products Regulatory Agency (MHRA) have described how the 10-Year Health Plan will lead to faster medicines access for patients in the NHS in England.

The treatment combines pembrolizumab, made by Merck Sharp & Dohme, with chemotherapy drugs carboplatin and paclitaxel. Pembrolizumab is an immunotherapy that helps the immune system recognise and ...

This update to the NICE HealthTech programme manual sets out in greater detail methods to be used by the NICE HealthTech programme when developing HealthTech guidance. This includes approaches for ...

After four years of transformational leadership, NICE CEO Dr Sam Roberts will step down at the end of the year to support her children through a difficult time.

This summary report is based on the NICE assumptions used in the resource impact template. Users can amend the 'Inputs and eligible population' and 'Unit costs' worksheets in the template to reflect ...

Vanzacaftor-tezacaftor-deutivacaftor (Alyftrek) is available on the NHS as a possible treatment for cystic fibrosis. It is for people 6 years and over who have at least 1 F508del mutation in the ...

Glofitamab with gemcitabine and oxaliplatin for treating relapsed or refractory diffuse B-cell lymphoma [ID6202] ...

REGN5458 for treating relapsed or refractory multiple myeloma [ID6609] Awaiting development GID-TA11810 Expected publication date: TBC ...

Suggested remit: To appraise the clinical and cost effectiveness of olezarsen within its marketing authorisation for treating familial chylomicronaemia syndrome. Key events during the development of ...

The recorded number of people referred to access NHS Talking Therapy services in 2023 to 2024 was 1.26 million (NHS Digital). Of this group, 672,000 people referred completed a course of treatment.